Mizuho raised the firm’s price target on Amgen to $235 from $223 and keeps a Neutral rating on the shares. The analyst updated the company’s model post the Q1 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Drugmakers work to make treatments to maintain weight loss, WSJ reports
- Fly Insider: Theravance Bio, Amgen among week’s notable insider trades
- CytomX Therapeutics upgraded to Buy from Hold at Jefferies
- Amgen price target raised to $325 from $315 at BofA
- Amgen price target lowered to $328 from $332 at RBC Capital